June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
The secretome of Mesenchymal stem cells protects both primary trabecular meshwork cells and retina ganglion cells
Author Affiliations & Notes
  • Christophe Roubeix
    Institut de la Vision, Paris, France
  • David Godefroy
    Institut de la Vision, Paris, France
  • Ivana IVKOVIC
    Institut de la Vision, Paris, France
  • Fradot Valerie
    Institut de la Vision, Paris, France
  • Serge A Picaud
    Institut de la Vision, Paris, France
  • Stephane Melik Parsadaniantz
    Institut de la Vision, Paris, France
  • Françoise Baudouin
    Institut de la Vision, Paris, France
  • Christophe Baudouin
    Institut de la Vision, Paris, France
  • Footnotes
    Commercial Relationships Christophe Roubeix, None; David Godefroy, None; Ivana IVKOVIC, None; Fradot Valerie, None; Serge Picaud, None; Stephane Melik Parsadaniantz, None; Françoise Baudouin, None; Christophe Baudouin, LABORATOIRES THEA (C)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 2411. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Christophe Roubeix, David Godefroy, Ivana IVKOVIC, Fradot Valerie, Serge A Picaud, Stephane Melik Parsadaniantz, Françoise Baudouin, Christophe Baudouin; The secretome of Mesenchymal stem cells protects both primary trabecular meshwork cells and retina ganglion cells. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):2411.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To investigate the effect of Mesenchymal Stem Cells (MSCs) secretome (MSC-CM) on primary human trabecular meshwork cells and primary retinal ganglion cells

Methods: Primary human trabecular meshwork (hTM) cells (ScienceCell) from passage 1 to 8 were cultured in 6-well plates till 90% confluence before exposure to MSC-CM, TGF-β2 (20µg/ml) or both for 3 or 72 hours. We investigated the hTM-myofibroblast phenotype transition induced by TGF-β2+/-MSC-CM, and α-SMA, col3 and col4 mRNA level expression after 72h. Next, hTM exposure to TGF-β2+/-MSC-CM for 3h, we looked for the Akt- and myosin (MLC) phosporylation using Western-Blot assays. Purified primary RGCs was obtained from rat retina using immunopanning methods. Cells were seeded in 96-well plates at 12 000cells/well and maintained for 6 days in neurobasal+glutamine (NBAg), MSC-CM or NBAg+B27 medium. Cell viability was evaluated by calcein green fluorescence using live-dead test kit and a cell counting software.

Results: MSC-CM displayed favorable effects on viability, contractibility and phenotype conservation of hTM cells especially by impeding the deleterious effect of TGF-β2. MSC-CM clearly triggered the phosphorylation of the antiapoptotic Akt pathway resulting in an increased survival as proved in an in vitro BAK cytotoxic model. MSC-CM significantly inhibited the TGF-β2-dependent MLC phosphorylation on hTM and α-SMA, col3 and col4 mRNA increase. Furthermore, MSC-CM promoted cell viability and growth in a purified primary culture of rat RGC in vitro.

Conclusions: Through these in vitro approaches, we highlighted the beneficial effects of MSC-CM on primary cells directly involved in the physiopathology features of glaucoma. These results support the promising concept of MSCs-based therapy to treat glaucoma disease.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×